Mipomersen
Mipomersen
复制标题
DOI：
10.2165/11533460-000000000-00000
复制
发表时间：
2010-01-01
影响因子：
3
通讯作者：
中科院分区：
文献类型：
--
作者：
Genzyme Corporation和Isis Pharmaceuticals已就皮下注射米泊美生（ISIS 147764; ISIS 301012; ISIS 301012;米泊美生钠）的开发达成全球许可和合作协议。Mipomersen是一种针对载脂蛋白B-100（apo B-100）mRNA的寡核苷酸反义抑制剂，目前正在美国、欧盟、巴西、加拿大、南非和东南亚进行III期临床评价，用于治疗家族性高胆固醇血症（一种ha型高脂蛋白血症）和严重高胆固醇水平或冠心病高风险患者的高胆固醇血症。本文综述了这一新化合物的发展历史和科学概况。
Genzyme Corporation and Isis Pharmaceuticals have a worldwide licensing and collaboration agreement for the development of subcutaneous mipomersen (ISIS 147764; ISIS 301012; ISIS301012; mipomersen-sodium). Mipomersen, an oligonucleotide antisense inhibitor directed against apolipoprotein B-100 (apoB-100) mRNA, is in phase III clinical evaluation for the treatment of familial hypercholesterolemia, a form of type ha hyperlipoproteinemia, and hypercholesterolemia in patients with severely high cholesterol levels or at high risk for coronary heart disease in the US, European Union, Brazil, Canada, South Africa, and South East Asia. This review discusses the development history and scientific profile of this new compound.